SCHEMBL6367148

SCHEMBL6367148

CCOC(=O)C(C=O)c1ccc(OCc2ccccc2)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
APP P05067 5/20 0.51
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 1/20 0.50
F2 P00734 1/20 0.48
F10 P00742 1/20 0.48
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
F7 P08709 1/20 0.48
F3 P13726 1/20 0.48
PRSS3 P35030 1/20 0.48
ALDH1A1 P00352 2/20 0.48
HTT P42858 1/20 0.48
MTNR1A P48039 2/20 0.47
MTNR1B P49286 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100604 0.94 LMNA (0.51) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL6246976 0.88 HPGD (0.55) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL30100618 0.86 SMPD1 (0.48) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL30100613 0.86 KDM4E (0.45) HPGDNPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6372129 0.85 CA12 (0.49) SMN1; SMN2MEN1POLBGAAKMT2A
SCHEMBL14167822 0.84 HPGD (0.56) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL9676540 0.83 HPGD (0.53) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL6366936 0.83 HPGD (0.55) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL27085659 0.81 KDM4E (0.48) HPGDNPC1RAB9ASMN1; SMN2APP
SCHEMBL30100605 0.81 KDM4E (0.44) HPGDNPC1RAB9ASMN1; SMN2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6838478-B2 Amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2005-01-04 US disclosed
EP-0910573-B1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRAZENECA AB (SE) 2003-01-29 EP disclosed
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-14 US disclosed
US-6255301-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2001-07-03 US disclosed
EP-0910573-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-04-28 EP disclosed
WO-1997046577-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors F2, SERPINC1, FGB HPGD 2067/4885NPC1 4343/4885RAB9A 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.